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 Activation of poly(ADP-ribose) polymerase-1 (PARP-1) and 
its subsequent cleavage are early markers of apoptosis. 
PARP-1 is associated with DNA repair and so chromosome 
stability, cell cycle regulation, as well as tumorigenesis. To 
investigate the role of PARP-1 expression in colorectal car-
cinoma and its metastasis of liver, we compared the expres-
sion of PARP-1 in primary colorectal cancers with (n=15) 
and without liver metastasis (n=17) using a semi-quantitative 
reverse transcription - polymerase chain reaction. We also 
examined the expressions of poly(ADP-ribose) (PAR) and 
p53 in these tumors by immunohistochemistry. A signifi-
cantly higher PARP-1 mRNA expression was noted in tu-
mors with liver metastasis than those without liver metas-
tasis (p<0.01). Colorectal cancers positively stained for p53 
exhibited significantly higher PARP-1 mRNA expression than 
p53-negative tumors (p<0.01). The PAR labeling index (LI) 
of tumors with metastasis (0.33 ± 0.33) was not signifi-
cantly different (p=0.35) from that of tumors without liver 
metastasis (0.38 ± 0.19). p53-positive tumors tended to have 
higher PAR LI levels than p53-negative tumors (p=0.08). Our 
findings suggest that PARP-1 may contribute to liver me-
tastasis due to its DNA repair activity, resulting in sur-
vival of the tumor cells with accumulation of metastatic-
related gene's damages. Detailed analysis of PARP-1 may be 
useful in cancer research and/or cancer therapy. 
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Introduction
 Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear 
protein found in most of the eukaryotes, with the ex-
ception of yeast". PARP-1 gene is mapped on chromo-
some 1g41-42 in human". PARP-1 activation and sub-
sequent cleavage are well known as early markers of 
apoptosis 2). Intranuclear expression of PARP-1 is mar-
ginal in cells without DNA damages'', but it is explo-
sively increased when DNA strand breaks are induced 
by some DNA damaging agents or y-irradiation3' . 
PARP-1 binds to the site of DNA breaks, and cata-
lyzes the production of poly(ADP-ribose) (PAR). PARP-
1 is thought as a DNA strand break sensing molecule, 
and PAR is as a regulator of various nuclear proteins, 
for example, p53 4', histon H 1 and 1-1213 ', topoisomerase 
I4,5'. PARP-16', DNA-dependent protein kinase", DNA 
ligase 8', and DNA polymerase 8' . Therefore, PARP-1 is 
supposed to be associated with DNA repair system and 
so chromosome stability. 
 PARP-1 was reported to be involved in cell cycle 
regulation" and in malignant transformation"'. In im-
mortalized fibroblasts originally derived from PARP-
1-1- mice, p53 expression was reduced, and PAR, which 
covalently bound to p53, was absent"'. Inhibition of 
PARP activity by chemical inhibitors and ultraviolet 
light rendered mice or rats susceptible to carcinogenic 
agents, and resulted in the occurrence of various tu-
mors: hepatocellular carcinoma"), skin cancer"), ade-
noma, and sarcoma"'. These associations suggest a 
role of PARP-1 in suppressing tumorigenesis. However, 
the study of PARP-1 and PAR in human cancer tissue 
has been rarely seen, and their relevance of these 
molecules to metastasis has not been investigated. 
 In this study, we hypothesized that, among several 
clones that compose primary colorectal cancer, a 
PARP-1 deficient clone might metastasize because the 
damages of metastatic-related genes could not be re-
paired due to its insufficient DNA repair capacity. To 
study the relation between DNA repair capacity
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correlated with PARP-1 expression and liver metasta-
sis in human cancer, we investigated the expression of 
PARP-1, PAR, and p53 protein in primary colorectal 
cancers with or without liver metastasis.
Materials and Methods
Tumor samples
 Fifteen primary tumor specimens obtained from co-
lorectal cancer patients with liver metastasis were ex-
amined. Thirteen patients had synchronous liver me-
tastasis, and two had metachronous liver metastasis. 
As controls, we examined 17 specimens of primary co-
lorectal cancers obtained from patients who did not 
develop liver metastasis during a period of more than 
5 post-operative years. All patients underwent surgical 
resection at the Division of Surgical Oncology, Department 
of Translational Medical Sciences, Nagasaki University 
Graduate School of Biomedical Sciences. Samples were 
frozen at -80°C immediately after surgery. The pa-
tients ranged in age between 41 and 81 years (mean, 
62 years), and included 22 males and 10 females. All 
surgical samples were examined histopathologically'4', 
and classified by the American Joint Committee on 
Cancer Classification"'. There were 9 well-differentiated 
and 22 moderately-differentiated adenocarcinomas, and 
one was poor differentiated. In the patients, 13 were 
with stage IV, 6 with stage III, and 11 with stage II 
disease. No patient had other distant metastasis at the 
time of surgery and none of the patients had received 
radiation therapy or chemotherapy prior to surgery.
Semi-quantitative reverse transcription - polymerase chain 
reaction (R T-PCR) for PARP-1 mRNA
 Total RNA was extracted from frozen tissues using 
TRIzol Regent (Life Technologies, Rockville, MD) fol-
lowing the procedures recommended by the manufac-
turer. One step RT-PCR was performed from the pre-
pared total RNA (about l,ug) using an RT-PCR high-
Plus- kit (TOYOBO, Tokyo) according to the instructions 
provided by the manufacturer. Semi-quantitative RT-
PCR was used to analyze PARP-1 expression. Primer 
sequences used for RT-PCR are as follows: PARP-1: 
forward primer, 5'-GAGCGATGCCTATTACTGCAC-3', 
reverse primer, 5'-GAACAACTCCTGAAGGCTCTTG-3;' 16' 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH): 
forward primer, 5 ' -TCCACCACCCTGTTGCTGTA-3 ', 
reverse primer, 5 ' -ACCACAGTCCATGCCATCAC-3 '. 
One step RT-PCR was performed at 60°C for 30 min 
and 94°C for 2 min for 19-40 cycles using a step cycle
program at 94°C for lmin and 62°C for 1.5 min in a 
Perkin-Elmer thermal cycler (Foster City, CA), with a 
25-,u l reaction mixture containing 2 mM Mn(OAc) z , 
300 u M each deoxynucleotide, 400 nM each prirner, 
and 2.5 units rTth DNA polymerase in the appropriate 
buffer. After PCR, 9 ul of the reaction mixture were 
electrophoresed with 1 ,ul of the lOx loading die on a 
2% Nusive 3:1 agarose gel (Biocompare, Inc., Burlingame, 
CA) containing ethidium bromide. Estimation of the 
band intensity of PCR fragments was performed using a 
scanner and Scion image software (Scion Corporation, 
Frederick, MD). Agarose gels were photographed and 
their digital images were captured using the scanner. 
The scan data were saved and imported into the 
Scion image software for subsequent analysis. Band 
intensities were compared between PARP-1 and G3PDH 
for quantification after the same number of PCR cy-
cles, at a point at which the PCR reaction had not 
reached a plateau (Figure 1).
PARP-1 /G3PDH
Figure 1. Semi-quantitative reverse transcriptase-polymerase 
chain reaction (RT-PCR) for poly(ADP-ribose) polymerase-1 
(PARP-1) mRNA. PCR was performed for three consecutive 
cycles. The band intensity of PARP-1 was compared with 
that of glyceraldehyde-3-phosphate dehydrogenase (G3PDH), 
a house keeping gene, after the same number of cycles, be-
fore PCR reaction reached a plateau.
Immunohistochemistry for PAR and P53
 Immunohistochemical studies were performed on 5-
,um thick sections of formalin-fixed, paraffin-embedded 
specimens. An immunoperoxidase method, using a 
LSAB2 kit (Dako, Glostrup, Denmark), was used to de-
tect p53 and PAR in deparaffinized tissue sections. 
After microwave processing for 10 min in 10 mM cit-
ric acid buffer (pH 6.0), the tissue sections were incu-
bated for 5 min at room temperature in hydrogen per-
oxide (H202) to inhibit endogenous peroxide activity. 
Tissue sections were then incubated for 5 min at room 
temperature in phosphate buffered saline (PBS) con-
taining 1 % bovine serum albumin (BSA). Anti-human 
p53 protein (clone D07) (Dako), that recognizes an 
epitope located between amino acids 19 to 26 in both 
wild-type and mutant p53 protein, and monoclonal an-
tibody to PAR (clone 10H) (Alexis Biochemicals, Lausen,
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Switzerland) were used as primary antibodies. Tissue 
sections were incubated overnight with a 1:50 dilution 
of D07 monoclonal antibody or a 1:200 dilution of 10H 
monoclonal antibody in a moist chamber at 4°C. As a 
negative control, we added normal mouse IgG instead 
of the primary antibody. After incubation, the speci-
mens were treated by biotin-labeled goat anti-mouse 
immunoglobulin and streptavidin-conjugated horserad-
ish peroxidase. The peroxidase reaction was performed 
using diaminobenzidine as chromogen and H202. Tissue 
sections were counterstained with hematoxylin. We 
examined at least 1000 tumor cells and designated the 
sample as positive for p53 protein when at least 10% 
of tumor cells displayed strong nuclear staining. For 
PAR expression, the PAR labeling index (LI) was de-
fined as the percentage of positively stained nuclei ob-
served on counting more than 1000 tumor cells.
cancers positive for p53 (n=15) exhibited significantly 
higher PARP-1 mRNA expression than p53 negative 
tumors (n=17, 0.79±2.24 vs. 0.32--:L0.84, p<0.01, Figure 
2B).
PAR expression
 PAR immunoreactivity was localized in the nuclei of 
tumor cells and infiltrating lymphocytes with homoge-
neous intensity, but we only counted tumor cells in 
this study (Figure 3B). PAR expression did not corre-
late significantly with age, gender, histological type or 
PARP-1 mRNA expression. The PAR LI of tumors with 
liver metastasis (0.33±0.33, n=15) was not significantly 
different from that of tumors without liver metastasis 
(0.38±0.19, n=17, p=0.35). The PAR LI of p53-positive 
tumors (0.42±0.19, n=15) tended to be higher than
Statistical analyses
 Statistical analyses were performed using the com-
puter program STATISTICA TM(StatSoft, Tulsa, OK). 
Data are expressed as mean ± SD. Data were proc-
essed using the Mann-Whitney U test, Welch's T test, 
Fisher's exact test, and likelihood ratio test. The corre-
lation between PARP-1 mRNA and PAR LI was ana-
lyzed by Spearman's rank correction. A P value of 
less than 0.05 denoted the presence of a statistically 
significant difference.
Results
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 There were no significant differences in age (p=0.57), 
gender (p=0.89) or histological type (p=0.38) between 
patients with colorectal cancers and liver metastasis 
(n=15) and those without liver metastasis (n=17).
PARP-1 mRNA expression
 PARP-1 mRNA expression did not show any signifi-
cant differences according to age, gender or histological 
type. The mean expression level of PARP-1 mRNA in 
tumors with liver metastasis (0.91±2.10) was signifi-
cantly higher than those without liver metastasis (0.04 
±0.07, p<0.01, Figure 2A). The tumors with liver me-
tastasis had significantly higher PARP-1 mRNA ex-
pression than those without liver metastasis (p<0.01). 
p53 immunoreactivity was localized in the nuclei of 
tumor cells (Figure 3A). Fifteen of 32 (47%) colorectal 
cancers were p53-positive. Five of 15 (33%) tumors with 
liver metastasis were p53-positive, compared with 10 
of 17 (59%) tumors without metastasis (p=0.14). Colorectal
 B) 
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Figure2. Expression of poly(ADP-ribose) polymerase-1(PARP-
1) mRNA in primary colorectal tumors. (A) PARP-1 expres-
sion in tumors with liver metastasis (n=15) and without liver 
metastasis (n=17) (0.91±2.1 vs. 0.04±0.07, p<0.01). (B) PARP-
1 expression in p53- negative (n=17) and p53-positive (n=15) 
tumors (0.32±0.84 vs. 0.79±2.24, p<0.01). The ordinate repre-
sents the relative band intensity of PARP-1/G3PDH. Data are 
mean ± SD.
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that of p53-negative tumors (0.23±0.30, n=17, p=0.08, 
Figure 4).
Discussion
Figure 3. Immunohistochemical staining of p53 and poly 
(ADP-ribose). (A) p53 immunoreactivity (brown) was localized 
in the nuclei of tumor cells( X 200). (B) Poly(ADP-ribose) 
immunoreactivity (brown) was localized in the nuclei of 
tumor cells and infiltrating lymphocytes with homogeneous 
intensity (X200).
p53-negative 
  tumor 
  (n=17)
p53-positive 
  tumor 
  (n=15)
Figure 4. Poly(ADP-ribose) labeling index (PAR LI) in p53-
negative (n=17) , and p53-positive (n=15) tumors (0.23 ± 0.30 
vs. 0.42 ± 0.19, p=0.08) . Data are mean ± SD.
 In this study, we focused on an intra-nuclear multi-
functional enzyme, PARP-1, and investigated the asso-
ciation among PARP-1 and PAR expression and can-
cer metastasis in primary colorectal cancers with or 
without liver metastasis. Contrary to our expectation, 
the mean expression level of PARP-1 mRNA in pri-
mary tumors with liver metastasis was significantly 
higher than that of tumors without liver metastasis. 
 DNA-dependent protein kinase (DNA-PK) is required 
for the rejoining of double-strand DNA breaks, and 
plays a critical role in DNA repair. PARP-1 adds PAR 
to the DNA-PK catalytic subunit, and activates DNA-P 
K''. Thus, PARP-1 is considered to facilitate double-
strand DNA break repair by stimulating the protein 
kinase activity of DNA-PK. Our finding of a signifi-
cantly high PARP-1 mRNA in primary tumors with 
liver metastasis could be explained by the following 
mechanism. In fact, liver is supposed to be a unfavor-
able environment for colorectal cancer cells 17,, espe-
cially at early phase of liver metastasis. A report 
using melanoma cells suggested most of tumor cells 
reached liver were apoptotic, and finally they could 
survive only 36%18'. Therefore, colorectal cancer cells 
with high PARP expression may survive despite ge-
netic damage due to the high DNA repair activity, 
whereas those cells with low levels of PARP expres-
sion may succumb to apoptosis. Moreover, because the 
mRNA expression of cell cycle regulators, such as 
cyclin A and 131 and B2, were decreased in PARP-1' 
mouse fibroblasts` ', PARP-1 expression may contribute 
to cell cycle progression mediated by cyclins. Therefore, 
it might be possible to speculate that colorectal cancer 
cells with high PARP expression could proliferate even 
in the liver. In this regard, Bieche et al. reported that 
PARP-1 mRNA expression was higher in human breast 
cancer tissue than in adjacent normal breast tissues"'. 
Nomura et al. found that PARP-1 mRNA expression was 
elevated in hepatocellular carcinoma but not in nor-
mal liver 20'. These data suggest an important role of 
enhanced PARP-1 expression in human cancers, in ac-
cordance with our finding that PARP-1 may contrib-
ute to liver metastasis by increasing survival of the 
cells with metastatic potential. 
  In the present study, the expression of PARP-1 
mRNA and PAR was not in parallel. PAR production 
was controlled not only by PARP-1, but also by many 
factors, such as the amount of catalytic substrate
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nicotinamide adenine dinucleotide (NAD' ), the degree 
of DNA damage, and the rapid degeneration of PAR 
by poly(ADP-ribose) glicohydrolase3'. Therefore, PAR 
production was not always dependent upon the amount 
of PARP-1. Moreover, although PARP-1 has a most 
powerful PARP activity"', other PARP enzymes, such 
as PARP-2 and tankylase22', may be involved. 
 With respect to p53, Simbulan-Rosenthal et al. re-
ported that p53 protein in PARP-1-"- immortalized 
mouse cells decreased, compared to that of wild-type 
cells, and that p53 expression level was partially re-
stored by the reintroduction of PARP-1 cDNA23'. These 
results suggested that PARP-1 might be involved in 
p53 stabilization and accumulation. In the present 
study, we found that p53 expression was significantly 
correlated with the expression of PARP-1, and tended 
to be associated with PAR labeling index, confirming 
the relationship between p53 and poly(ADP-ribosyl) 
ation in human tissues, at least partly. It is most 
likely that direct binding of PAR to p53 protein in 
the nucleus may contribute to prolongation of the half 
life of p53 protein, and thus enhance p53 accumula-
tion. Despite the link between PARP-1 mRNA and liver 
metastasis or PARP-1 and p53, why p53 did not corre-
late liver metastasis? The contradiction may be as-
cribed to the small number of samples in this study 
and numerous samples are required for further inves-
tigation. 
 It is possible that PARP-1 inhibition may be benefi-
cial for cancer therapy. PARP-1 inhibits topoisomerase 
I activity by poly(ADP-ribosyl) ation in the presence 
of NAD`, the catalytic substrate of PARP-12"). It has 
been recently reported that the combining use of 
PARP-1 inhibitor and topoisomerase I inhibitor show 
the synergistic cytotoxic effect"'. Therefore, assessment 
of PARP-1 activity in tumors may be useful for can-
cer chemotherapy. 
 In conclusion, we found the possible relationship be-
tween PARP-1 expression and liver metastasis in colo-
rectal cancer. The detailed analysis of PARP-1 may be 
useful for further cancer study and also cancer ther-
apy.
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